- Home
- NCA vs RCEL Comparison
NCA vs RCEL Comparison
Compare NCA & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- RCEL
- Stock Information
- Founded
- NCA 1987
- RCEL N/A
- Country
- NCA United States
- RCEL United States
- Employees
- NCA N/A
- RCEL N/A
- Industry
- NCA Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- NCA Finance
- RCEL Health Care
- Exchange
- NCA Nasdaq
- RCEL Nasdaq
- Market Cap
- NCA 284.4M
- RCEL 308.6M
- IPO Year
- NCA N/A
- RCEL N/A
- Fundamental
- Price
- NCA $8.64
- RCEL $9.75
- Analyst Decision
- NCA
- RCEL Buy
- Analyst Count
- NCA 0
- RCEL 5
- Target Price
- NCA N/A
- RCEL $17.25
- AVG Volume (30 Days)
- NCA 59.6K
- RCEL 186.1K
- Earning Date
- NCA 01-01-0001
- RCEL 02-13-2025
- Dividend Yield
- NCA 3.92%
- RCEL N/A
- EPS Growth
- NCA N/A
- RCEL N/A
- EPS
- NCA N/A
- RCEL N/A
- Revenue
- NCA N/A
- RCEL $64,251,000.00
- Revenue This Year
- NCA N/A
- RCEL $62.11
- Revenue Next Year
- NCA N/A
- RCEL $31.19
- P/E Ratio
- NCA N/A
- RCEL N/A
- Revenue Growth
- NCA N/A
- RCEL 28.14
- 52 Week Low
- NCA $7.77
- RCEL $7.51
- 52 Week High
- NCA $9.12
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- NCA 59.18
- RCEL 50.10
- Support Level
- NCA $8.53
- RCEL $8.37
- Resistance Level
- NCA $8.70
- RCEL $11.25
- Average True Range (ATR)
- NCA 0.06
- RCEL 0.55
- MACD
- NCA 0.00
- RCEL 0.22
- Stochastic Oscillator
- NCA 63.53
- RCEL 47.92
About NCA Nuveen California Municipal Value Fund
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.